Form 4: Mirum Pharmaceuticals CEO Acquires Shares Through Employee Stock Purchase Plan

Mirum Pharmaceuticals CEO, Christopher Peetz, acquired 65 shares of common stock through the company's Employee Stock Purchase Plan on November 8, 2024.

Summary

• Christopher Peetz, CEO of Mirum Pharmaceuticals, acquired 65 shares of common stock on November 8, 2024.
• The shares were purchased through the company's Employee Stock Purchase Plan.
• The price per share was $21.046.
• Following the transaction, Mr. Peetz directly owns 126,848 shares and indirectly owns 208,570 shares through The Peetz Family Trust.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a positive but not overly significant sentiment. The CEO's participation in the employee stock purchase plan is a positive sign.

Positives

• The CEO's participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Industry Context

This is a routine transaction for a company with an employee stock purchase plan, and is not unusual for a CEO to participate.

Comparison to Industry Standards

• Employee stock purchase plans are a common practice among publicly traded companies, including those in the pharmaceutical industry.
• Many companies offer similar plans to incentivize employee ownership and align their interests with shareholders.
• The level of participation by executives varies, but it is not uncommon for CEOs to participate in these plans.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it demonstrates the CEO's confidence in the company.

Key Dates

Keywords

Mirum Pharmaceuticals, Christopher Peetz, Employee Stock Purchase Plan, stock acquisition, insider trading, MIRM